Copyright Reports & Markets. All rights reserved.

Global Patient In-vivo Dosimetry (IVD) System Market Research Report 2021

Request for Sample of this report
Buy now

1 Patient In-vivo Dosimetry (IVD) System Market Overview

  • 1.1 Product Overview and Scope of Patient In-vivo Dosimetry (IVD) System
  • 1.2 Patient In-vivo Dosimetry (IVD) System Segment by Type
    • 1.2.1 Global Patient In-vivo Dosimetry (IVD) System Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Portable
    • 1.2.3 Fixed
  • 1.3 Patient In-vivo Dosimetry (IVD) System Segment by Application
    • 1.3.1 Global Patient In-vivo Dosimetry (IVD) System Sales Comparison by Application: (2021-2027)
    • 1.3.2 Medical
    • 1.3.3 Scientific Research
    • 1.3.4 Others
  • 1.4 Global Patient In-vivo Dosimetry (IVD) System Market Size Estimates and Forecasts
    • 1.4.1 Global Patient In-vivo Dosimetry (IVD) System Revenue 2016-2027
    • 1.4.2 Global Patient In-vivo Dosimetry (IVD) System Sales 2016-2027
    • 1.4.3 Patient In-vivo Dosimetry (IVD) System Market Size by Region: 2016 Versus 2021 Versus 2027

2 Patient In-vivo Dosimetry (IVD) System Market Competition by Manufacturers

  • 2.1 Global Patient In-vivo Dosimetry (IVD) System Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Patient In-vivo Dosimetry (IVD) System Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Patient In-vivo Dosimetry (IVD) System Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Patient In-vivo Dosimetry (IVD) System Manufacturing Sites, Area Served, Product Type
  • 2.5 Patient In-vivo Dosimetry (IVD) System Market Competitive Situation and Trends
    • 2.5.1 Patient In-vivo Dosimetry (IVD) System Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Patient In-vivo Dosimetry (IVD) System Players Market Share by Revenue
    • 2.5.3 Global Patient In-vivo Dosimetry (IVD) System Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Patient In-vivo Dosimetry (IVD) System Retrospective Market Scenario by Region

  • 3.1 Global Patient In-vivo Dosimetry (IVD) System Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global Patient In-vivo Dosimetry (IVD) System Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America Patient In-vivo Dosimetry (IVD) System Market Facts & Figures by Country
    • 3.3.1 North America Patient In-vivo Dosimetry (IVD) System Sales by Country
    • 3.3.2 North America Patient In-vivo Dosimetry (IVD) System Revenue by Country
    • 3.3.3 United States
    • 3.3.4 Canada
  • 3.4 Europe Patient In-vivo Dosimetry (IVD) System Market Facts & Figures by Country
    • 3.4.1 Europe Patient In-vivo Dosimetry (IVD) System Sales by Country
    • 3.4.2 Europe Patient In-vivo Dosimetry (IVD) System Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Patient In-vivo Dosimetry (IVD) System Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Patient In-vivo Dosimetry (IVD) System Sales by Region
    • 3.5.2 Asia Pacific Patient In-vivo Dosimetry (IVD) System Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 China Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
  • 3.6 Latin America Patient In-vivo Dosimetry (IVD) System Market Facts & Figures by Country
    • 3.6.1 Latin America Patient In-vivo Dosimetry (IVD) System Sales by Country
    • 3.6.2 Latin America Patient In-vivo Dosimetry (IVD) System Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Patient In-vivo Dosimetry (IVD) System Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Patient In-vivo Dosimetry (IVD) System Sales by Country
    • 3.7.2 Middle East and Africa Patient In-vivo Dosimetry (IVD) System Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Patient In-vivo Dosimetry (IVD) System Historic Market Analysis by Type

  • 4.1 Global Patient In-vivo Dosimetry (IVD) System Sales Market Share by Type (2016-2021)
  • 4.2 Global Patient In-vivo Dosimetry (IVD) System Revenue Market Share by Type (2016-2021)
  • 4.3 Global Patient In-vivo Dosimetry (IVD) System Price by Type (2016-2021)

5 Global Patient In-vivo Dosimetry (IVD) System Historic Market Analysis by Application

  • 5.1 Global Patient In-vivo Dosimetry (IVD) System Sales Market Share by Application (2016-2021)
  • 5.2 Global Patient In-vivo Dosimetry (IVD) System Revenue Market Share by Application (2016-2021)
  • 5.3 Global Patient In-vivo Dosimetry (IVD) System Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Landauer
    • 6.1.1 Landauer Corporation Information
    • 6.1.2 Landauer Description and Business Overview
    • 6.1.3 Landauer Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Landauer Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.1.5 Landauer Recent Developments/Updates
  • 6.2 Chiyoda Technol Corporation
    • 6.2.1 Chiyoda Technol Corporation Corporation Information
    • 6.2.2 Chiyoda Technol Corporation Description and Business Overview
    • 6.2.3 Chiyoda Technol Corporation Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Chiyoda Technol Corporation Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.2.5 Chiyoda Technol Corporation Recent Developments/Updates
  • 6.3 Mirion Technologies
    • 6.3.1 Mirion Technologies Corporation Information
    • 6.3.2 Mirion Technologies Description and Business Overview
    • 6.3.3 Mirion Technologies Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Mirion Technologies Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.3.5 Mirion Technologies Recent Developments/Updates
  • 6.4 Thermo Fisher Scientific
    • 6.4.1 Thermo Fisher Scientific Corporation Information
    • 6.4.2 Thermo Fisher Scientific Description and Business Overview
    • 6.4.3 Thermo Fisher Scientific Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Thermo Fisher Scientific Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.4.5 Thermo Fisher Scientific Recent Developments/Updates
  • 6.5 Fuji Electric
    • 6.5.1 Fuji Electric Corporation Information
    • 6.5.2 Fuji Electric Description and Business Overview
    • 6.5.3 Fuji Electric Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Fuji Electric Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.5.5 Fuji Electric Recent Developments/Updates
  • 6.6 Hitachi Aloka
    • 6.6.1 Hitachi Aloka Corporation Information
    • 6.6.2 Hitachi Aloka Description and Business Overview
    • 6.6.3 Hitachi Aloka Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Hitachi Aloka Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.6.5 Hitachi Aloka Recent Developments/Updates
  • 6.7 Bertin Instruments
    • 6.6.1 Bertin Instruments Corporation Information
    • 6.6.2 Bertin Instruments Description and Business Overview
    • 6.6.3 Bertin Instruments Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Bertin Instruments Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.7.5 Bertin Instruments Recent Developments/Updates
  • 6.8 Tracerco
    • 6.8.1 Tracerco Corporation Information
    • 6.8.2 Tracerco Description and Business Overview
    • 6.8.3 Tracerco Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Tracerco Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.8.5 Tracerco Recent Developments/Updates
  • 6.9 ATOMTEX
    • 6.9.1 ATOMTEX Corporation Information
    • 6.9.2 ATOMTEX Description and Business Overview
    • 6.9.3 ATOMTEX Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 ATOMTEX Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.9.5 ATOMTEX Recent Developments/Updates
  • 6.10 Panasonic
    • 6.10.1 Panasonic Corporation Information
    • 6.10.2 Panasonic Description and Business Overview
    • 6.10.3 Panasonic Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Panasonic Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.10.5 Panasonic Recent Developments/Updates
  • 6.11 Polimaster
    • 6.11.1 Polimaster Corporation Information
    • 6.11.2 Polimaster Patient In-vivo Dosimetry (IVD) System Description and Business Overview
    • 6.11.3 Polimaster Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Polimaster Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.11.5 Polimaster Recent Developments/Updates
  • 6.12 Renri
    • 6.12.1 Renri Corporation Information
    • 6.12.2 Renri Patient In-vivo Dosimetry (IVD) System Description and Business Overview
    • 6.12.3 Renri Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Renri Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.12.5 Renri Recent Developments/Updates
  • 6.13 RadPro International GmbH
    • 6.13.1 RadPro International GmbH Corporation Information
    • 6.13.2 RadPro International GmbH Patient In-vivo Dosimetry (IVD) System Description and Business Overview
    • 6.13.3 RadPro International GmbH Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 RadPro International GmbH Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.13.5 RadPro International GmbH Recent Developments/Updates
  • 6.14 Ludlum Measurements
    • 6.14.1 Ludlum Measurements Corporation Information
    • 6.14.2 Ludlum Measurements Patient In-vivo Dosimetry (IVD) System Description and Business Overview
    • 6.14.3 Ludlum Measurements Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Ludlum Measurements Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.14.5 Ludlum Measurements Recent Developments/Updates
  • 6.15 XZ LAB
    • 6.15.1 XZ LAB Corporation Information
    • 6.15.2 XZ LAB Patient In-vivo Dosimetry (IVD) System Description and Business Overview
    • 6.15.3 XZ LAB Patient In-vivo Dosimetry (IVD) System Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 XZ LAB Patient In-vivo Dosimetry (IVD) System Product Portfolio
    • 6.15.5 XZ LAB Recent Developments/Updates

7 Patient In-vivo Dosimetry (IVD) System Manufacturing Cost Analysis

  • 7.1 Patient In-vivo Dosimetry (IVD) System Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Patient In-vivo Dosimetry (IVD) System
  • 7.4 Patient In-vivo Dosimetry (IVD) System Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Patient In-vivo Dosimetry (IVD) System Distributors List
  • 8.3 Patient In-vivo Dosimetry (IVD) System Customers

9 Patient In-vivo Dosimetry (IVD) System Market Dynamics

  • 9.1 Patient In-vivo Dosimetry (IVD) System Industry Trends
  • 9.2 Patient In-vivo Dosimetry (IVD) System Growth Drivers
  • 9.3 Patient In-vivo Dosimetry (IVD) System Market Challenges
  • 9.4 Patient In-vivo Dosimetry (IVD) System Market Restraints

10 Global Market Forecast

  • 10.1 Patient In-vivo Dosimetry (IVD) System Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Patient In-vivo Dosimetry (IVD) System by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Patient In-vivo Dosimetry (IVD) System by Type (2022-2027)
  • 10.2 Patient In-vivo Dosimetry (IVD) System Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Patient In-vivo Dosimetry (IVD) System by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Patient In-vivo Dosimetry (IVD) System by Application (2022-2027)
  • 10.3 Patient In-vivo Dosimetry (IVD) System Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Patient In-vivo Dosimetry (IVD) System by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Patient In-vivo Dosimetry (IVD) System by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Portable
    Fixed

    Segment by Application
    Medical
    Scientific Research
    Others

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    China Taiwan
    Indonesia
    Thailand
    Malaysia
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Landauer
    Chiyoda Technol Corporation
    Mirion Technologies
    Thermo Fisher Scientific
    Fuji Electric
    Hitachi Aloka
    Bertin Instruments
    Tracerco
    ATOMTEX
    Panasonic
    Polimaster
    Renri
    RadPro International GmbH
    Ludlum Measurements
    XZ LAB

    Buy now